In the more recently reported PERTAIN trial advanced HR+/HER2+ breast cancer patients were treated with an aromatase inhibitor (AI) and trastuzumab either with or without pertuzumab treatment [31]. The gene discussed is ERBB2; the disease is breast carcinoma.